Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
-
Larry K. Golightly
,
Gerard R. Barber
Abstract
Background: Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury.
Methods: Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone.
Results: A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135).
Conclusions: In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81.10.1016/S0140-6736(10)61350-5Suche in Google Scholar
2. Bulbulia R, Bowman K, Wallendszus K, Parish S, Armitage J, Peto R, et al. Heart protection study collaborative group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,356 high-risk individuals: a randomised controlled trial. Lancet 2011;378:2013–20.10.1016/S0140-6736(11)61125-2Suche in Google Scholar
3. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Heart protection study collaborative group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. Br Med J 2006;333:1145.10.1136/bmj.38993.731725.BESuche in Google Scholar
4. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin [letter]. Ann Intern Med 1991;114:342.10.7326/0003-4819-114-4-342_1Suche in Google Scholar
5. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis and simvastatin use [letter]. Nephron 1991;57:365–6.10.1159/000186289Suche in Google Scholar
6. Bizzaro N, Bagolin E, Lilani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin [letter]. Clin Chem 1992;38:1504.10.1093/clinchem/38.8.1504Suche in Google Scholar
7. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient [letter]. Am J Med 2000;108:351–2.10.1016/S0002-9343(99)00320-4Suche in Google Scholar
8. Federman DG, Hussain F, Walters JB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001;94:1023–6.10.1097/00007611-200194100-00017Suche in Google Scholar
9. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002;35:e111–2.10.1086/344179Suche in Google Scholar PubMed
10. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, et al. Fatal toxic myopathy attributed to methylprednisolone and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol 2008;27:129–31.10.1007/s10067-007-0696-9Suche in Google Scholar PubMed
11. Schick BA, Laaksonen R, Frohlich JJ, Päiva H, Lehtimäki T, Humphries KH, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007;81:650–3.10.1038/sj.clpt.6100124Suche in Google Scholar
12. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther 2005;19:403–14.10.1007/s10557-005-5686-zSuche in Google Scholar
13. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781–90.10.1016/S0140-6736(07)60716-8Suche in Google Scholar
14. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658–69.10.1016/S0140-6736(10)60310-8Suche in Google Scholar
15. FDA Drug Safety Communication. New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed 16 April 2012.Suche in Google Scholar
16. Oleson FB Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai J-J, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948–53.10.1128/AAC.44.11.2948-2953.2000Suche in Google Scholar PubMed PubMed Central
17. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–81.10.1086/420818Suche in Google Scholar PubMed
18. Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use [letter]. Int J Antimicrob Agents 2007;30:472–4.10.1016/j.ijantimicag.2007.07.009Suche in Google Scholar PubMed
19. Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006;42:e108–10.10.1086/504379Suche in Google Scholar PubMed
20. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin [letter]. J Antimicrob Chemother 2006;57:578–9.10.1093/jac/dki476Suche in Google Scholar PubMed
21. Odero RO, Cleveland KO, Gelfand S. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor [letter]. J Antimicrob Chemother 2009;63:1299–300.10.1093/jac/dkp127Suche in Google Scholar PubMed
22. Bland CM, Brookstaver PB, Thomas S. Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin [letter]. Int J Antimicrob Agents 2011;38:549–50.10.1016/j.ijantimicag.2011.08.003Suche in Google Scholar PubMed
23. Cubicin® injection [package insert]. Lexington, MA: Cubist Pharmaceuticals Inc, 2012.Suche in Google Scholar
24. Pasternak RC, Smith SC Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024–8.10.1161/01.CIR.0000032466.44170.44Suche in Google Scholar PubMed
25. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674–80.10.1345/aph.1H423Suche in Google Scholar PubMed
26. Rowan C, Brinker AD, Nourjah P, Chang J, Mosholder A, Barrett JS, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009;18:301–9.10.1002/pds.1711Suche in Google Scholar PubMed PubMed Central
27. Vickers S, Duncan CA, Chen I-W, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138–45.Suche in Google Scholar
28. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157–81.10.1124/pr.110.002857Suche in Google Scholar PubMed
29. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56: 120–4.10.1046/j.1365-2125.2003.01833.xSuche in Google Scholar PubMed PubMed Central
30. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505–12.10.1124/dmd.30.5.505Suche in Google Scholar PubMed
31. Chen C, Mireles RJ, Campbell SC, Lin J, Mills JB, Xu JJ, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005;33:537–46.10.1124/dmd.104.002477Suche in Google Scholar PubMed
32. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda I, et al. The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 2008;359:789–99.10.1056/NEJMoa0801936Suche in Google Scholar PubMed
33. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The Clinical Pharmacogenomics Implementation Consortium. CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012;92:112–7.10.1038/clpt.2012.57Suche in Google Scholar PubMed PubMed Central
34. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788–97.10.1161/CIRCULATIONAHA.106.624890Suche in Google Scholar PubMed
35. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf 2012;11:439–44.10.1517/14740338.2012.670633Suche in Google Scholar PubMed
36. Martin PD, Dane AL, Schneck DW, Warwick MJ. Disposition of new HMG-CoA reductase inhibitor ZD4522 following dosing in healthy subjects [abstract]. J Clin Pharmacol 2000;40:1056.Suche in Google Scholar
37. McCormick AD, McKillop D, Dutters CJ, Miles GS, Baba T, Touchi A, et al. ZD4522: an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J Clin Pharmacol 2000;40:1055.Suche in Google Scholar
38. Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011;10:969–86.10.1517/14740338.2012.626764Suche in Google Scholar PubMed
39. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565–81.10.1016/j.clpt.2006.09.003Suche in Google Scholar PubMed
40. Sacher J, Weigl L, Werner, M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005;314:1032–41.10.1124/jpet.105.086462Suche in Google Scholar PubMed
41. Mullen PJ, Lüscher B, Scharnagl H, Krähenbühl, Brecht K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol 2010;79:1200–9.10.1016/j.bcp.2009.12.007Suche in Google Scholar PubMed
42. Kwak H-B, Thalacker-Mercer A, Anderson EJ, Lin C-T, Kane DA, Lee N-S, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52:198–207.10.1016/j.freeradbiomed.2011.10.449Suche in Google Scholar PubMed PubMed Central
43. Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11–6.10.1016/j.trsl.2008.11.002Suche in Google Scholar PubMed
44. Fowler VG Jr., Boucher HW, Corey R, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65.10.1056/NEJMoa053783Suche in Google Scholar PubMed
45. Bhavani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations of creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50: 1568–74.10.1086/652767Suche in Google Scholar PubMed
46. Sbrana F, Di Paolo A, Pasanisi EM, Tagliaferri E, Arvia C, Puntoni M, et al. Administration interval and daptomycin toxicity: a case report of rhabdomyolysis [letter]. J Chemother 2010;22:434–5.10.1179/joc.2010.22.6.434Suche in Google Scholar
47. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000;46:523–6.10.1093/jac/46.4.523Suche in Google Scholar
48. DePestel DD, Herschberger E, Lamp KC, Malani PN. Safety and clinical outcomes among older adults receiving daptomycin therapy: insights from a patient registry. Am J Geriatr Pharmacother 2010;8:551–61.10.1016/S1543-5946(10)80004-2Suche in Google Scholar
49. Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, et al. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol 2011;75:63–9.Suche in Google Scholar
50. Kostrominova TY, Coleman S, Oleson FB, Faulkner JA, Larkin LM. Effect of daptomycin on primary rat muscle cell cultures in vitro. In Vitro Cell Dev Biol Anim 2010;46:613–8.10.1007/s11626-010-9311-5Suche in Google Scholar PubMed
51. Kostrominova TY, Hassett CA, Rader EP, Davis C, Larkin LM, Coleman S, et al. Characterization of skeletal muscle effects associated with daptomycin in rats. Muscle Nerve 2010;42: 385–93.10.1002/mus.21691Suche in Google Scholar PubMed
52. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 1992;36:318–25.Suche in Google Scholar
53. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004;150:137–47.10.1016/j.cbi.2004.08.004Suche in Google Scholar PubMed
54. Parra-Ruiz J, Dueñas-Gutiérrez C, Tomás-Jiménez C, Linares-Palomino JP, Garrido-Gomez J, Hernández-Quero J. Safety analysis of high-dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis 2012;31:1771–4.10.1007/s10096-011-1500-ySuche in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects
- Opinion Paper
- An ethical framework for the disposal of autologous stem cells
- Original Articles
- A prospective observational study of medication errors in general medicine department in a tertiary care hospital
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression
- Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
- Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
- Congress Abstracts
- Post-Congress Satellite Meeting/Pharmacogenomics and theranostics in practice
Artikel in diesem Heft
- Masthead
- Masthead
- Editorial
- Clinical pharmacology of drug metabolism and drug interactions: clinical, interethnical and regulatory aspects
- Opinion Paper
- An ethical framework for the disposal of autologous stem cells
- Original Articles
- A prospective observational study of medication errors in general medicine department in a tertiary care hospital
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression
- Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds
- Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control
- Congress Abstracts
- Post-Congress Satellite Meeting/Pharmacogenomics and theranostics in practice
